Cite
Feasibility of CD19 CAR T-cell therapy in patients with cardiac lymphoma.
MLA
Kuipers, Maria T., et al. “Feasibility of CD19 CAR T-Cell Therapy in Patients with Cardiac Lymphoma.” Leukemia & Lymphoma, vol. 65, no. 3, Mar. 2024, pp. 399–402. EBSCOhost, https://doi.org/10.1080/10428194.2023.2288804.
APA
Kuipers, M. T., Spanjaart, A. M., Bonifazi, F., diBlasi, R., Zinzani, P. L., Thieblemont, C., Baudet, M., Biemond, B. J., Kok, W. E. M., & Kersten, M. J. (2024). Feasibility of CD19 CAR T-cell therapy in patients with cardiac lymphoma. Leukemia & Lymphoma, 65(3), 399–402. https://doi.org/10.1080/10428194.2023.2288804
Chicago
Kuipers, Maria T., Anne M. Spanjaart, Francesca Bonifazi, Roberta diBlasi, Pier L. Zinzani, Catherine Thieblemont, Mathilde Baudet, Bart J. Biemond, Wouter E. M. Kok, and Marie J. Kersten. 2024. “Feasibility of CD19 CAR T-Cell Therapy in Patients with Cardiac Lymphoma.” Leukemia & Lymphoma 65 (3): 399–402. doi:10.1080/10428194.2023.2288804.